drugset / Trial / NCT02422719
Radotinib as 3rd or Later Line Therapy in CP-CML
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether radotinib is effective and safe for patients with chronic myeloid leukemia, chronic phase who are intolerable or resistant to prior 2 or more tyrosine kinase inhibitors.
Timeline
- Start
- 2015-04
- Primary completion
- 2019-03
- Completion
- 2019-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Radotinib | Small molecule | 400 mg | — |